NPI: 1013916352 · RALEIGH, NC 27609 · General Acute Care Hospital · NPI assigned 07/19/2005
Authorized official SMITH, JOHN controls 20+ related entities in our dataset. Read more
| Authorized Official | SMITH, JOHN (VP FINANCE) |
| NPI Enumeration Date | 07/19/2005 |
Other providers sharing the same authorized official: SMITH, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 25,229 | $1.04M |
| 2019 | 19,292 | $783K |
| 2020 | 14,716 | $421K |
| 2021 | 28,460 | $1.12M |
| 2022 | 35,918 | $1.83M |
| 2023 | 33,747 | $1.70M |
| 2024 | 17,029 | $949K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9,370 | 8,369 | $2.40M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 10,330 | 9,364 | $2.01M |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 13,306 | 12,356 | $1.58M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 14,586 | 11,262 | $372K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 30,711 | 24,791 | $200K |
| 80053 | Comprehensive metabolic panel | 22,078 | 17,515 | $162K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2,912 | 2,576 | $108K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1,154 | 1,054 | $103K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3,678 | 3,123 | $88K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1,235 | 715 | $84K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1,119 | 788 | $63K |
| 36415 | Collection of venous blood by venipuncture | 27,478 | 23,981 | $61K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1,163 | 1,053 | $59K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 815 | 755 | $53K |
| 96375 | Therapeutic injection; each additional sequential IV push | 674 | 560 | $42K |
| 36591 | 1,332 | 689 | $41K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1,134 | 1,040 | $34K |
| 0002A | 540 | 516 | $32K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 1,390 | 1,164 | $32K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 985 | 901 | $28K |
| 0001A | 501 | 490 | $27K | |
| J7030 | Infusion, normal saline solution , 1000 cc | 2,385 | 2,028 | $17K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 535 | 493 | $14K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 313 | 301 | $13K |
| 83690 | 1,999 | 1,749 | $13K | |
| 80061 | Lipid panel | 679 | 637 | $12K |
| 81025 | 1,565 | 1,400 | $12K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 26 | 24 | $11K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 195 | 187 | $9K |
| 83735 | 1,600 | 1,144 | $9K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 1,343 | 1,154 | $9K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 53 | 48 | $8K |
| 0072A | 121 | 109 | $8K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 261 | 224 | $8K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 193 | 184 | $7K |
| 71046 | Radiologic examination, chest; 2 views | 203 | 177 | $7K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 882 | 810 | $7K |
| 82728 | 694 | 619 | $7K | |
| 85027 | 884 | 711 | $6K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 167 | 147 | $6K |
| 81001 | 2,098 | 1,869 | $6K | |
| J3490 | Unclassified drugs | 1,532 | 1,004 | $5K |
| 82378 | 333 | 211 | $5K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 147 | 129 | $5K |
| 0071A | 111 | 94 | $5K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 147 | 129 | $5K |
| 86780 | 271 | 232 | $5K | |
| 84443 | Thyroid stimulating hormone (TSH) | 258 | 226 | $5K |
| 87081 | 493 | 488 | $4K | |
| 83550 | 452 | 398 | $3K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 30 | 26 | $3K |
| J7050 | Infusion, normal saline solution, 250 cc | 706 | 376 | $3K |
| 83540 | 520 | 449 | $3K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 39 | 39 | $3K |
| 84484 | 287 | 210 | $2K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 26 | 25 | $2K |
| 83615 | 298 | 227 | $2K | |
| 87631 | 28 | 24 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 113 | 104 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 1,346 | 1,192 | $2K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 47 | 39 | $1K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 42 | 26 | $1K |
| 87634 | 14 | 12 | $1K | |
| 85730 | 239 | 219 | $1K | |
| 86850 | 74 | 63 | $1K | |
| 0004A | 25 | 20 | $1K | |
| 85610 | 295 | 269 | $942.76 | |
| 81003 | 377 | 335 | $836.96 | |
| 84439 | 86 | 65 | $815.53 | |
| 85046 | 187 | 172 | $795.79 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 77 | 61 | $702.52 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 106 | 90 | $651.28 |
| 84403 | 65 | 49 | $641.82 | |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 13 | 12 | $555.84 |
| 84153 | 80 | 63 | $539.39 | |
| 71045 | Radiologic examination, chest; single view | 12 | 12 | $450.09 |
| 82784 | 21 | 15 | $312.44 | |
| 82607 | 14 | 14 | $293.68 | |
| 86803 | 15 | 15 | $280.20 | |
| 86901 | 73 | 62 | $273.22 | |
| 86900 | 73 | 62 | $273.22 | |
| 82553 | 29 | 25 | $208.65 | |
| J2704 | Injection, propofol, 10 mg | 108 | 74 | $200.40 |
| 82248 | 44 | 36 | $179.24 | |
| 82950 | 28 | 24 | $178.62 | |
| 82550 | 30 | 26 | $152.32 | |
| 84165 | 14 | 14 | $128.44 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 16 | 16 | $112.48 |
| 83521 | 18 | 12 | $92.11 | |
| 82040 | 16 | 12 | $74.77 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 161 | 132 | $64.16 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 27 | 27 | $50.89 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 26 | 25 | $49.61 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 61 | 59 | $39.94 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 43 | 42 | $24.22 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 17 | 15 | $23.78 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 112 | 106 | $23.58 |
| 84460 | 38 | 24 | $1.44 | |
| D2930 | Prefabricated stainless steel crown - primary tooth | 12 | 12 | $1.33 |
| 84450 | 38 | 24 | $1.28 | |
| 91307 | 269 | 234 | $0.00 | |
| 84075 | 16 | 12 | $0.00 | |
| 91300 | 1,477 | 1,342 | $0.00 | |
| 84155 | 16 | 12 | $0.00 | |
| 82247 | 16 | 12 | $0.00 |